Patient experience in HCV therapy: what really matters

The Lancet Gastroenterology and Hepatology

Volumn 1, Issue 2, 2016, Pages 90-92

  Buti, María ^a   Esteban, Rafael ^a  

^a INSTITUTO DE SALUD CARLOS III   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

RIBAVIRIN; SOFOSBUVIR; VELPATASVIR; ANTIVIRUS AGENT;

ANTIVIRAL THERAPY; COGNITIVE DEFECT; FATIGUE; HEPATITIS C; HUMAN; LIVER CELL CARCINOMA; LIVER FIBROSIS; MORTALITY RATE; NOTE; PERSONAL EXPERIENCE; PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; QUALITY OF LIFE; SHORT FORM 36; VIRUS LOAD; CHRONIC HEPATITIS C; COMBINATION DRUG THERAPY; HEPACIVIRUS; RETROSPECTIVE STUDY; TREATMENT OUTCOME;

ANTIVIRAL AGENTS; DRUG THERAPY, COMBINATION; HEPACIVIRUS; HEPATITIS C; HEPATITIS C, CHRONIC; HUMANS; RETROSPECTIVE STUDIES; TREATMENT OUTCOME;

EID: 84995898110     PISSN: 24681253     EISSN: None     Source Type: Journal    
DOI: 10.1016/S2468-1253(16)30020-6     Document Type: Note

References (8)

1. 1 European Association for Study of Liver. EASL recommendations on treatment of hepatitis C 2015. J Hepatol 63 (2015), 199–236.
2. 2 van der Meer, AJ, Wedemeyer, H, Feld, JJ, et al. Life expectancy in patients with chronic HCV infection and cirrhosis compared with a general population. JAMA 312 (2014), 1927–1928.
3. 3 Negro, F, Forton, D, Craxì, A, Sulkowski, MS, Feld, JJ, Manns, MP, Extrahepatic morbidity and mortality of chronic hepatitis C. Gastroenterology 149 (2015), 1345–1360.
4. 4 Younossi, Z, Henry, L, Systematic review: patient-reported outcomes in chronic hepatitis C—the impact of liver disease and new treatment regimens. Aliment Pharmacol Ther 4 (2015), 497–520.
5. 5 Gerber, L, Estep, M, Stepanova, M, Escheik, C, Weinstein, A, Younossi, ZM, Effects of viral eradication with ledipasvir and sofosbuvir, with or without ribavirin, on measures of fatigue in patients with chronic hepatitis C virus infection. Clin Gastroenterol Hepatol, 14, 2016, 156 64.e3.
6. 6 Younossi, Z, Stepanova, M, Charlton, M, et al. Patient-reported outcomes with sofosbuvir and velpatasvir with or without ribavirin for hepatitis C virus-related decompensated cirrhosis: an exploratory analysis from the randomised, open-label ASTRAL-4 phase 3 trial. Lancet Gastroenterol Hepatol, 2016 published online August 3. http://dx.doi.org/10.1016/S2468-1253(16)30009-7.
7. 7 Curry, MP, O'Leary, JG, Bzowej, N, et al. Sofosbuvir and velpatasvir for HCV in patients with decompensated cirrhosis. N Engl J Med 373 (2015), 2618–2628.
8. 8 Younossi, ZM, Stepanova, M, Henry, L, Nader, F, Hunt, S, An in-depth analysis of patient-reported outcomes in patients with chronic hepatitis C treated with different anti-viral regimens. Am J Gastroenterol 111 (2016), 808–816.